Table 1: Main characteristics of the 8 studies included in the meta-analysis.

First author Year (reference)Number of CRCs cohortMales/femalesColon/rectumVariables of adjustmentPrediagnosis PAPostdiagnosis PA

Campbell et al., 2013 [9]2293
CPS-II
1271/9911664/598Age, gender, stage, BMI, and tobacco≥8.75 MET hour/wk versus <3.5 MET hour/wk
RR CSS = 0.78 (0.57–1.08)
RR OS = 0.72 (0.58–0.89)
RR CSS = 0.87 (0.61–1.24)
RR OS = 0.58 (0.47–0.71)

Kuiper et al., 2012 [10]1339
WHI
0/1339404/96Age, time from diagnosis, BMI, stage, alcohol, tobacco, and HRT≥18 MET hour/wk versus no PA
HR CSS = 0.68 (0.41–1.13)
HR OS = 0.63 (0.42–0.96)
HR CSS = 0.29 (0.11–0.77)
HR OS = 0.41 (0.21–0.81)

Baade et al., 2011 [11]1825
Queensland
1089/7361163/662Age, gender, BMI, stage, tobacco, and type of therapy593 sufficiently active versus 748 sedentary
HR CSS = 0.88 (0.68–1.15)
HR OS = 0.75 (0.60–0.94)

Meyerhardt et al., 2009 [12]668
HPFS
661/0390/110Age, stage, colon/rectum, BMI, and tobacco≥27 MET hour/wk versus <3 MET hour/wk
HR CSS = 0.47 (0.24–0.92)
HR OS = 0.59 (0.41–0.86)

Meyerhardt et al., 2006 [13]573
NHS
0/573421/104Age, gender, BMI, stage, colon/rectum, CT, tobacco, and time from diagnosis≥18 MET hour/wk versus <3 MET hour/wk
HR CSS = 0.86 (0.44–1.67)
HR OS = 0.95 (0.57–1.59)
≥18 MET hour/wk versus <3 MET hour/wk
HR CSS = 0.39 (0.18–0.82)
HR OS = 0.43 (0.25–0.74)

Meyerhardt et al., 2006 [14]832
Stage III NCI
471/361832/0Age, gender, invasion, perforation, obstruction, CEA, BMI, CT arm, and PS18–27 MET hour/wk versus <3 MET hour/wk
HR RFS = 0.51 (0.26–1.01)
HR OS = 0.71 (0.32–1.59)

Haydon et al., 2006 [15]526
MCCS
270/256336/175Age, gender, BMI, and stagePA versus no PA
HR DFS = 0.73 (0.54–1.00)
HR OS = 0.77 (0.58–1.03)

CRC means colorectal cancer, PA: physical activity, MET: metabolic equivalent task, BMI: body mass index, CSS: cancer-specific survival, OS: overall survival, HRT: hormone replacement therapy, na: not available, CEA: carcinoembryonic antigen, CT: chemotherapy, and PS: performance status.